Comparison of Anti-Programmed Cell Death Ligand 1 Therapy Combinations vs Sunitinib for Metastatic Renal Cell Carcinoma: A Meta-analysis.
作者信息
Maiorano Brigida Anna, Ciardiello Davide, Maiello Evaristo, Roviello Giandomenico
机构信息
Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Foundation Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
Department of Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy.
出版信息
JAMA Netw Open. 2023 May 1;6(5):e2314144. doi: 10.1001/jamanetworkopen.2023.14144.
Abstract
摘要
相似文献
1
Comparison of Anti-Programmed Cell Death Ligand 1 Therapy Combinations vs Sunitinib for Metastatic Renal Cell Carcinoma: A Meta-analysis.抗程序性细胞死亡配体1疗法联合用药与舒尼替尼治疗转移性肾细胞癌的比较：一项荟萃分析
JAMA Netw Open. 2023 May 1;6(5):e2314144. doi: 10.1001/jamanetworkopen.2023.14144.
2
Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression.转移性透明细胞肾细胞癌对舒尼替尼有长期反应：一种与低 PD-L1 表达独立相关的独特表型。
Clin Genitourin Cancer. 2019 Jun;17(3):169-176.e1. doi: 10.1016/j.clgc.2019.01.014. Epub 2019 Feb 4.
3
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.帕博利珠单抗、依维莫司和舒尼替尼治疗转移性肾细胞癌患者的 PD-L1 表达与临床结局：METEOR 和 CABOSUN 随机临床试验分析。
Clin Cancer Res. 2019 Oct 15;25(20):6080-6088. doi: 10.1158/1078-0432.CCR-19-1135. Epub 2019 Aug 1.
4
Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.程序性细胞死亡蛋白 1 与程序性细胞死亡配体 1 抑制剂在转移性肾细胞癌中的肿瘤学和毒性结局差异：系统评价和荟萃分析。
Cancer Treat Rev. 2021 Sep;99:102242. doi: 10.1016/j.ctrv.2021.102242. Epub 2021 Jun 12.
5
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.avelumab 联合阿昔替尼对比舒尼替尼用于晚期肾细胞癌：来自 JAVELIN Renal 101 的日本亚组分析。
Cancer Sci. 2020 Mar;111(3):907-923. doi: 10.1111/cas.14294. Epub 2020 Feb 5.
6
The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.程序性死亡配体 1 预测转移性肾细胞癌患者接受免疫检查点抑制剂治疗的价值：系统评价和荟萃分析。
Eur Urol. 2021 Jun;79(6):783-792. doi: 10.1016/j.eururo.2020.10.006. Epub 2020 Nov 7.
7
Sunitinib in Patients with Metastatic Renal Cell Carcinoma with Favorable Risk: Be Aware of PD-L1 Expression.舒尼替尼治疗低危转移性肾细胞癌患者：注意 PD-L1 表达。
Med Sci (Basel). 2024 Sep 13;12(3):48. doi: 10.3390/medsci12030048.
8
Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.靶向程序性死亡配体 1 的 RNA 干扰抑制小鼠肾透明细胞癌 RenCa 模型中的肿瘤生长和对舒尼替尼的增敏作用。
Anticancer Res. 2019 Sep;39(9):4737-4742. doi: 10.21873/anticanres.13656.
9
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.在一项比较阿替利珠单抗单药或联合贝伐珠单抗与舒尼替尼治疗既往未治疗的转移性肾细胞癌的 2 期研究中患者报告的结局。
BJU Int. 2020 Jul;126(1):73-82. doi: 10.1111/bju.15058. Epub 2020 Apr 24.
10
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.阿替利珠单抗联合贝伐珠单抗对比舒尼替尼用于既往未接受治疗的转移性肾细胞癌患者（IMmotion151）：一项多中心、开放标签、III 期、随机对照临床试验。
Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.
引用本文的文献
1
Clinical outcome predictors for metastatic renal cell carcinoma: a retrospective multicenter real-life case series.转移性肾细胞癌的临床预后预测因素：一项回顾性多中心真实病例系列研究。
BMC Cancer. 2024 Jul 5;24(1):804. doi: 10.1186/s12885-024-12572-4.
2
Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials.抗血管生成-免疫检查点抑制剂联合治疗：III 期临床试验的经验教训。
Nat Rev Clin Oncol. 2024 Jun;21(6):468-482. doi: 10.1038/s41571-024-00886-y. Epub 2024 Apr 10.
3
First-line ICIs in renal cell carcinoma.一线免疫检查点抑制剂在肾细胞癌中的应用。
Hum Vaccin Immunother. 2023 Aug 1;19(2):2225386. doi: 10.1080/21645515.2023.2225386. Epub 2023 Jul 3.
本文引用的文献
1
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.阿替利珠单抗辅助治疗与安慰剂用于接受切除术治疗后复发风险增加的肾细胞癌患者（IMmotion010）：一项多中心、随机、双盲、III 期临床试验。
Lancet. 2022 Oct 1;400(10358):1103-1116. doi: 10.1016/S0140-6736(22)01658-0. Epub 2022 Sep 10.
2
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.帕博利珠单抗对比安慰剂用于肾透明细胞癌肾切除术患者的辅助治疗（KEYNOTE-564）：一项多中心、随机、双盲、安慰剂对照、III 期临床试验的 30 个月随访分析。
Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9.
3
Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm.抗程序性死亡蛋白1（anti-PD1）和抗程序性死亡配体1（anti-PD-L1）相似吗？非小细胞肺癌范例。
Oncol Rev. 2020 Jul 21;14(2):490. doi: 10.4081/oncol.2020.490. eCollection 2020 Jul 6.
4
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.阿替利珠单抗联合贝伐珠单抗对比舒尼替尼用于既往未接受治疗的转移性肾细胞癌患者（IMmotion151）：一项多中心、开放标签、III 期、随机对照临床试验。
Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.
5
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.阿维鲁单抗联合阿昔替尼与舒尼替尼治疗晚期肾细胞癌。
N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16.
6
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.阿替利珠单抗单药或联合贝伐珠单抗与舒尼替尼治疗肾细胞癌的临床活性和分子相关性。
Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4.
Zotero 插件